Extreme Stability of Chitotriosidase in Cerebrospinal Fluid makes it a Suitable Marker for Microglial Activation in Clinical Trials
2012 (English)In: Journal of Alzheimer's Disease, ISSN 1387-2877, Vol. 32, no 2, 273-276 p.Article in journal (Refereed) Published
Microglia is thought to be important in Alzheimer's disease. Therefore, our aim was to investigate the usefulness of the microglial marker chitotriosidase in clinical trials. Chitotriosidase was analyzed in cerebrospinal fluid from Alzheimer's disease patients on acetylcholine esterase inhibitors (AChEI) and in cerebrospinal fluid from multiple sclerosis patients before and after natalizumab treatment. Chitotriosidase activity was extremely stable during treatment with the non-inflammatory drug AChEI. However, the immunomodulatory treatment with natalizumab led to lower chitotriosidase activity. Thus, chitotriosidase may be useful in clinical trials where microglia is targeted or as a safety biomarker in other trials where the brain is a bystander organ.
Place, publisher, year, edition, pages
2012. Vol. 32, no 2, 273-276 p.
Alzheimer's disease, biomarker, cerebrospinal fluid, chitotriosidase, multiple sclerosis, stability
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-185656DOI: 10.3233/JAD-2012-120931ISI: 000309977800003PubMedID: 22785399OAI: oai:DiVA.org:uu-185656DiVA: diva2:572298